Physician profile
Amy Stone
NPI 1235108770
$69,733.75
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $20K · 2021: $24K · 2022: $10K · 2023: $812 · 2024: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $675 · Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $675.00 |
| Food and Beverage | $424.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46,109.34 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $11,129.28 | 2021 | |
| Abbvie INC. | $6,857.23 | 2022-2024 | Botox, Ubrelvy |
| Biohaven Pharmaceutical Holding Company LTD. | $4,040.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $962.67 | 2019-2024 | Austedo Xr, Ajovy |
| Ucb, INC. | $75.82 | 2019-2024 | Fintepla |
| Merz North America, INC. | $65.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.42 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $48.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $44.24 | 2019 | |
| Biogen, INC. | $40.04 | 2019 | |
| Amgen INC. | $34.56 | 2019 | |
| Pfizer INC. | $31.60 | 2019-2023 | |
| Emd Serono, INC. | $30.33 | 2019-2020 | |
| Ge Healthcare | $23.41 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $22.40 | 2019 | |
| Genzyme Corporation | $21.67 | 2019 | |
| Scilex Pharmaceuticals INC. | $20.99 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.04 | 2020 | |
| Adamas Pharmaceuticals, INC. | $17.52 | 2020 | |
| Upsher-Smith Laboratories LLC | $15.70 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.91 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.89 | 2019 | |
| Acadia Pharmaceuticals INC | $14.29 | 2020 | |
| Eisai INC. | $13.45 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.